WallStreetZenWallStreetZen

NASDAQ: IKT
Inhibikase Therapeutics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Inhibikase Therapeutics earnings were -$36.5M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest IKT earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$13.7M, up 12.7% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, IKT reported annual earnings of -$27.5M, with 44.6% growth.

IKT earnings history

Current Revenue
$0.0
Current Earnings
-$36.5M
Current Profit Margin
0%

IKT Return on Equity

Current Company
-79%
Current Industry
-60.2%
Current Market
31.3%
IKT's Return on Equity (-79%)... subscribe to Premium to read more.
High Return on Equity Performance

IKT undefined

Current Company
-70.9%
Current Industry
-2.5%
IKT is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when IKT announces earnings.

IKT undefined

Current Company
-42.63%
Current Industry
5.8%
IKT has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

IKT vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
IKT-$36.52M-$36.55MN/A-$0.59
RAPT-$113.03M-$116.51MN/A-$19.84
ENTA-$87.12M-$96.42MN/A-$4.54
CGENN/A-$14.15MN/A-$0.16
MOLN-$68.31M-$72.55MN/A-$2.07
View Top Biotech Stocks

Inhibikase Therapeutics Earnings Reports & History FAQ

What were Inhibikase Therapeutics's earnings last quarter?

On IKT's earnings call on Invalid Date, Inhibikase Therapeutics (NASDAQ: IKT) reported Q1 2025 earnings per share (EPS) of -$0.15, up 79.45% year over year. Total IKT earnings for the quarter were -$13.68 million. In the same quarter last year, Inhibikase Therapeutics's earnings per share (EPS) was -$0.73.

If you're new to stock investing, here's how to buy Inhibikase Therapeutics stock.

Is Inhibikase Therapeutics profitable or losing money?

As of the last Inhibikase Therapeutics earnings report, Inhibikase Therapeutics is currently losing money. Inhibikase Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$36.55 million, a 90.35% increase year over year.

What was IKT's earnings growth in the past year?

As of Inhibikase Therapeutics's earnings date in Invalid Date, Inhibikase Therapeutics's earnings has grown year over year. IKT earnings in the past year totalled -$36.55 million.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.